Physicians, Nurse practitioners, Physician assistants
|1.||Tailor abortive and prophylactic treatment for headache and migraine to the patient's symptom profile, prior response to medications, medical comorbidities and treatment preference||2.||Utilize multimodal treatment approaches to improve outcomes of patients with headaches and migraines|
|1.||Tailor abortive and prophylactic treatment for headache and migraine to the patient's symptom profile, prior response to medications, medical comorbidities and treatment preference|
|2.||Utilize multimodal treatment approaches to improve outcomes of patients with headaches and migraines|
Statement of Need
According to the 2010 Global Burden of Disease Study, headache represents one of the top 10 causes of disability, and migraine, in particular, is responsible for 3% of disability attributable to a specific disease. Although most headache patients are managed in the primary care setting, chronic headache remains the most common cause of neurological consultation. In the United States, the American Migraine Prevalence and Prevention (AMPP) study reported an overall prevalence of migraine headache of 11.7%, probable migraine of 4.5%, and chronic migraine (CM) of 1%. CM represents a more disabling and difficult-to-treat disorder than episodic migraine (EM). It is also the most common form of chronic daily headache seen in US clinics. However, CM is an underdiagnosed and undertreated disorder; only 20%-25% of patients who meet the criteria for CM receive appropriate diagnosis today.
CM can be considered a complication of EM with more frequent attacks and fewer pain-free intervals. The AMPP study found that compared with EM patients, CM patients have doubly higher rates of depression, anxiety and chronic pain. Other disorders that are often seen in CM patients include respiratory disorders, cardiac risk factors, diabetes, and obesity. Notably, as demonstrated by recent studies, appropriate preventive treatment for CM might lessen headache disability, associated comorbidities, and improve health-related quality of life. Since an increasing number of CM patients present to neurology and pain specialists, it is of key importance that these health care providers are kept up-to-date with evidence-based best practices in establishing correct diagnosis for CM and choosing appropriate multimodal treatment strategies.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and HealthmattersCME. Global is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient-care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Stephen D. Silberstein, MD, Chair||Nothing to disclose|
|David W. Dodick, MD||Consultant/Independent Contractor: Alcobra; Alder; Allergan; Amgen; Arteaus; Autonomic Technologies; Boston Scientific; Bristol-Myers Squibb; Colucid; Electrocore; Eli Lilly & Company; ENeura; Ethicon J&J; Impax; Labrys; Lundbeck; MAP Pharmaceuticals; Medtronic; Merck; Novartis; NuPathe; Pfizer; St Jude; Supernus; Teva; Tonix; Zogenix |
Alcobra; Alder; Allergan; Amgen; Arteaus; Autonomic Technologies; Boston Scientific; Bristol-Myers Squibb; Colucid; Electrocore; Eli Lilly & Company; ENeura; Ethicon J&J; Impax; Labrys; Lundbeck; MAP Pharmaceuticals; Medtronic; Merck; Novartis; NuPathe; Pfizer; St Jude; Supernus; Teva; Tonix; Zogenix
Allergan; American Academy of Neurology; Decision Resources; Healthlogix; IntraMed; John Wiley & Sons, Inc; Oxford University Press; SAGE Publishing; Starr Clinical; Sun Pharmaceuticals; Synergy; Universal Meeting Management; UptoDate; WebMD
|Name of Planner or Manager||Reported Financial Relationship|
|Andrea Funk||Nothing to disclose|
|Amanda Glazar, PhD||Nothing to disclose|
|James Murphy||Nothing to disclose|
|Supported Browsers: |
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above